<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-05-30T08:08:58Z</responseDate><request verb="GetRecord" identifier="oai:riuma.uma.es:10630/27536" metadataPrefix="mods">https://riuma.uma.es/rest/oai/request</request><GetRecord><record><header><identifier>oai:riuma.uma.es:10630/27536</identifier><datestamp>2026-02-03T12:27:56Z</datestamp><setSpec>com_10630_2254</setSpec><setSpec>col_10630_37959</setSpec></header><metadata><mods:mods xmlns:doc="http://www.lyncode.com/xoai" xmlns:mods="http://www.loc.gov/mods/v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
   <mods:name>
      <mods:namePart>Claros-Gil, Silvia</mods:namePart>
   </mods:name>
   <mods:name>
      <mods:namePart>Valverde Moreno, Nadia</mods:namePart>
   </mods:name>
   <mods:name>
      <mods:namePart>Zamorano-González, Pablo</mods:namePart>
   </mods:name>
   <mods:name>
      <mods:namePart>Romero-Zerbo, Silvana Yanina</mods:namePart>
   </mods:name>
   <mods:name>
      <mods:namePart>Lara Fernández, Estrella</mods:namePart>
   </mods:name>
   <mods:name>
      <mods:namePart>Boraldi, Federica</mods:namePart>
   </mods:name>
   <mods:name>
      <mods:namePart>Pavía-Molina, José</mods:namePart>
   </mods:name>
   <mods:name>
      <mods:namePart>García-Fernández, María Inmaculada</mods:namePart>
   </mods:name>
   <mods:name>
      <mods:namePart>Gago-Calderón, Belén</mods:namePart>
   </mods:name>
   <mods:name>
      <mods:namePart>Martín-Montañez, Elisa</mods:namePart>
   </mods:name>
   <mods:extension>
      <mods:dateAvailable encoding="iso8601">2023-09-15T11:37:16Z</mods:dateAvailable>
   </mods:extension>
   <mods:extension>
      <mods:dateAccessioned encoding="iso8601">2023-09-15T11:37:16Z</mods:dateAccessioned>
   </mods:extension>
   <mods:originInfo>
      <mods:dateIssued encoding="iso8601">2023</mods:dateIssued>
   </mods:originInfo>
   <mods:identifier type="uri">https://hdl.handle.net/10630/27536</mods:identifier>
   <mods:abstract>The neurodegenerative Parkinson’s disease (PD) affects 1–3% of the population aged over 65. A wide range of pathways and mechanisms are involved in its pathogenesis, such as oxidative stress, mitochondrial dysfunction, inflammation and neuronal glucocorticoid-induced toxicity, which ultimately produce a progressive loss of nigral dopamine neurons. Insulin-like growth factor II (IGF-II) has shown antioxidant and neuroprotective effects in some neurodegenerative disorders. Therefore, our aim was to study IGF-II protective effects against oxidative damage on a cellular combined model of PD and mild to moderate stress, based on corticosterone (CORT), an endocrine response marker to stress, and the dopaminergic neurotoxin 1-methyl-4-phenylpyridinium (MPP+). The dopaminergic neuronal cell line SN4741 (RRID:CVCL_S466) derived from mouse substantia nigra were exposed to 200 μM MPP+, 0.5 μM CORT or both, with or without 25 ng/mL IGF-II, for 2.5 or 6 h. Cell viability, oxidative stress parameters, mitochondrial and dopamine markers and intracellular signaling pathways were evaluated. The administration of MPP+ or CORT individually led to cell damage compared to control situations, whereas the combination of both drugs produced very considerable toxic synergistic effect. IGF-II counteracts the mitochondrial-oxidative damage, protecting dopaminergic neurons from death and neurodegeneration. IGF-II maintained the tyrosine hydroxylase expression and promotes nuclear factor (erythroid-derived 2)-like 2 antioxidant response in a glucocorticoid receptor-dependent pathway, preventing oxidative cell damage and maintaining mitochondrial function. This work revealed the potential neuroprotective role of IGF-II to protect nigral dopamine neurons against mitochondrial-oxidative damage induced by CORT and MPP+ was demonstrated. Thus, IGF-II is a potential therapeutic tool for prevention and treatment of PD patients suffering mild to moderate emotional stress.</mods:abstract>
   <mods:language>
      <mods:languageTerm>eng</mods:languageTerm>
   </mods:language>
   <mods:accessCondition type="useAndReproduction">open access</mods:accessCondition>
   <mods:subject>
      <mods:topic>Cerebro - Envejecimiento</mods:topic>
   </mods:subject>
   <mods:subject>
      <mods:topic>Parkinson, Enfermedad de</mods:topic>
   </mods:subject>
   <mods:subject>
      <mods:topic>Hormonas peptídicas</mods:topic>
   </mods:subject>
   <mods:titleInfo>
      <mods:title>Antioxidant and neuroprotective actions of IGF-II against glucocorticoid-induced  toxicity in dopaminergic neurons.</mods:title>
   </mods:titleInfo>
   <mods:genre>conference output</mods:genre>
</mods:mods>
</metadata></record></GetRecord></OAI-PMH>